In pre-clinical animal experiments, XG-102 and a similar peptidergic JNK-inhibitor conferred promising beneficial effects in models for cerebral ischemia ([27], [68], [69]), diabetes ([30], [70]), atherosclerosis ([32]) or lung inflammation (reviewed by [33], [35], [71]). Here, MAPK8 is linked to brain ischemia.